Technical Analysis for IMGN - ImmunoGen, Inc.

Grade Last Price % Change Price Change
A 31.23 0.00% 0.00
IMGN closed unchanged on Friday, February 9, 2024, on 4.92 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
5 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
Shooting Star Candlestick Bearish 94.46%
Lizard Bearish Bearish Day Trade Setup 94.46%
Doji - Bearish? Reversal 94.46%
NR7 Range Contraction 93.25%
Crossed Above 20 DMA Bullish 93.49%
20 DMA Resistance Bearish 105.33%
Crossed Above 50 DMA Bullish 105.33%
Fell Below 20 DMA Bearish 109.04%
Fell Below 50 DMA Bearish 109.04%
Gapped Down Weakness 109.04%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

ImmunoGen, Inc. Description

ImmunoGen, Inc. engages in the development of antibody-based anticancer therapeutics. The company develops its products using its targeted antibody payload (TAP) technology. Its product candidates include Trastuzumab emtansine, a Phase III clinical trial product for HER2+ metastatic breast cancer; lorvotuzumab mertansine, which is in Phase II clinical trial for the treatment of diagnosed metastatic small-cell lung cancer, as well as in a Phase I clinical trial for the treatment of multiple myeloma; IMGN853, a Phase I clinical trial product that targets over-expressed folate receptor 1 in ovarian cancer and other types of solid tumors, including non-small cell lung cancer; and IMGN529, a product in Phase I clinical trial for treatment of non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia. The company's compounds in earlier-stage of development comprise SAR3419, a Phase II clinical trial product to treat CD19-expressing B-cell malignancies, such as NHL and B-cell acute lymphoblastic leukemia; BT-062, a Phase I product, which targets CD138 antigen found on multiple myeloma and various solid tumors; SAR650984, a Phase I clinical trial product for CD38-targeting hematological malignancies; SAR566658, a Phase I clinical trial product for DS6-expressing solid tumors; BAY 94-9343, a Phase I clinical trial product for mesothelin-expressing solid tumors; and Amgen 1 and Amgen 2, which are phase I clinical trial compounds. It has collaborations with Amgen Inc.; Bayer HealthCare; Biotest AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; Genentech, Inc; Sanofi; and Hoffman-La Roche Inc. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Clinical Medicine Solid Tumors Drugs Monoclonal Antibodies Breast Cancer Lymphoma Non Small Cell Lung Cancer Ovarian Cancer Treatment Of Breast Cancer Small Cell Lung Cancer Multiple Myeloma Medical Research Antibody Drug Conjugate Hematological Malignancies Her2 Chronic Lymphocytic Leukemia Lymphocytic Leukemia Clinical Trial Product Cancer Therapeutics Acute Lymphoblastic Leukemia Immunogen Metastatic Breast Cancer B Cell Acute Lymphoblastic Leukemia Mesothelin

Is IMGN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 31.25
52 Week Low 3.61
Average Volume 9,877,238
200-Day Moving Average 19.00
50-Day Moving Average 29.35
20-Day Moving Average 29.66
10-Day Moving Average 29.76
Average True Range 0.35
RSI (14) 82.49
ADX 44.67
+DI 48.37
-DI 9.75
Chandelier Exit (Long, 3 ATRs) 30.21
Chandelier Exit (Short, 3 ATRs) 30.19
Upper Bollinger Bands 30.73
Lower Bollinger Band 28.58
Percent B (%b) 1.23
BandWidth 7.24
MACD Line 0.53
MACD Signal Line 0.48
MACD Histogram 0.0413
Fundamentals Value
Market Cap 8.72 Billion
Num Shares 279 Million
EPS -0.28
Price-to-Earnings (P/E) Ratio -111.54
Price-to-Sales 30.33
Price-to-Book 15.53
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 31.28
Resistance 3 (R3) 31.28 31.26 31.27
Resistance 2 (R2) 31.26 31.25 31.26 31.26
Resistance 1 (R1) 31.25 31.24 31.24 31.25 31.26
Pivot Point 31.23 31.23 31.23 31.23 31.23
Support 1 (S1) 31.22 31.22 31.21 31.22 31.20
Support 2 (S2) 31.20 31.21 31.20 31.20
Support 3 (S3) 31.19 31.20 31.19
Support 4 (S4) 31.19